"Our decision to treat typically needs to be made on the balance of likelihood, before the diagnosis of an associated disease process can be fully established, with definitive tests for multiple ...

Outcomes in acute optic neuritis tend to be worse at 6 months for men, patients who are older and those with poorer ...

ZUG, Switzerland, January 6, 2025 – Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced ...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ACUITY ...

Young people could be spared from going blind by a new genetic risk tool that could also help diagnose multiple sclerosis (MS) earlier, to start effective treatments. Optic neuritis is a condition ...

Optic neuritis is a rare autoimmune disease characterized by the inflammation of the optic nerve. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TRE-515 for the ...

Erythropoietin (EPO), shown in early studies to potentially provide neuroprotection for patients with optic neuritis, failed to provide any significant neuroprotection in comparison with placebo in a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 2 ACUITY trial evaluated OCS-05 at 2 mg/kg/day ...